檢索結果 - Li‐Tain Yeh

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males

    Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males 由 Zancong Shen, Colin Rowlings, Brad Kerr, V. Hingorani, Kimberly J. Manhard, Barry Quart, Li‐Tain Yeh, Chris Storgard

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia

    Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia 由 R. Fleischmann, Bradley M. Kerr, Li‐Tain Yeh, Matt Suster, Zancong Shen, E. Polvent, V. Hingorani, Barry Quart, Kimberly J. Manhard, Jeffrey N. Miner, Scott Baumgartner

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer

    RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer 由 Cory Iverson, Gary Larson, Chon Lai, Li‐Tain Yeh, Claudia Dadson, Paul Weingarten, T.C. Appleby, Todd Vo, Andreas Maderna, Jean‐Michel Vernier, Robert Hamatake, Jeffrey N. Miner, Barry Quart

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

    Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney 由 Jeffrey N. Miner, Philip K. Tan, David Hyndman, Sha Liu, Cory Iverson, Payal Nanavati, David Hagerty, Kimberly J. Manhard, Zancong Shen, Jean‐Luc Girardet, Li‐Tain Yeh, Robert Terkeltaub, Barry Quart

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

    Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer 由 Colin D. Weekes, Daniel D. Von Hoff, Alex A. Adjei, Diane P. Leffingwell, Sabine Eckhardt, Lia Gore, Karl D. Lewis, Glen J. Weiss, Ramesh K. Ramanathan, Grace K. Dy, Wen Wang, Beth Sheedy, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li‐Tain Yeh, Ronald L. Dubowy, Michael Jeffers, Prabhu Rajagopalan, Neil J. Clendeninn

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: